Equities research analysts predict that Verastem, Inc. (NASDAQ:VSTM – Get Rating) will announce ($0.10) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Verastem’s earnings, with the highest EPS estimate coming in at ($0.08) and the lowest estimate coming in at ($0.11). Verastem also posted earnings per share of ($0.10) in the same quarter last year. The business is scheduled to issue its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Verastem will report full year earnings of ($0.38) per share for the current year, with EPS estimates ranging from ($0.43) to ($0.33). For the next year, analysts forecast that the business will post earnings of ($0.23) per share, with EPS estimates ranging from ($0.30) to ($0.16). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that follow Verastem.
Verastem (NASDAQ:VSTM – Get Rating) last announced its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). Verastem had a negative return on equity of 84.99% and a negative net margin of 2,007.44%.
VSTM has been the subject of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Verastem in a research note on Friday, April 1st. Royal Bank of Canada initiated coverage on shares of Verastem in a research note on Thursday, April 14th. They issued an “outperform” rating and a $5.00 target price for the company. Truist Financial initiated coverage on shares of Verastem in a research note on Wednesday, March 9th. They issued a “buy” rating and a $6.00 target price for the company. HC Wainwright reiterated a “buy” rating on shares of Verastem in a research note on Tuesday, March 29th. Finally, StockNews.com lowered shares of Verastem from a “hold” rating to a “sell” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $5.63.
Several institutional investors have recently made changes to their positions in the company. LPL Financial LLC bought a new position in shares of Verastem in the fourth quarter worth approximately $26,000. Envestnet Asset Management Inc. bought a new position in Verastem during the fourth quarter valued at approximately $28,000. Virtu Financial LLC bought a new position in Verastem during the fourth quarter valued at approximately $33,000. XTX Topco Ltd bought a new position in Verastem during the first quarter valued at approximately $37,000. Finally, Clear Creek Financial Management LLC bought a new position in Verastem during the fourth quarter valued at approximately $38,000. 73.25% of the stock is currently owned by hedge funds and other institutional investors.
Shares of VSTM stock traded up $0.01 during trading hours on Friday, hitting $1.08. 1,778,481 shares of the company were exchanged, compared to its average volume of 1,669,593. The company has a market capitalization of $201.27 million, a PE ratio of -2.63 and a beta of 0.88. Verastem has a 52 week low of $1.00 and a 52 week high of $4.94. The company has a current ratio of 6.72, a quick ratio of 5.69 and a debt-to-equity ratio of 0.34. The business has a 50 day moving average of $1.41 and a two-hundred day moving average of $1.82.
About Verastem (Get Rating)
Verastem, Inc, a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK.